C-Jun/C7ORF41/NF-κB axis mediates hepatic inflammation and lipid accumulation in NAFLD.

Nonalcoholic fatty liver disease (NAFLD) is an expanding health problem worldwide. Although many studies have made great efforts to elucidate the pathogenesis of NAFLD, the molecular basic remains poorly understood. Here, we showed that hepatic C7ORF41, a critical regulator of innate immune response, was markedly decreased in diet or genetic-induced NAFLD model. We also demonstrated that C7ORF41 overexpression significantly ameliorated hepatic inflammation and lipid accumulation in palmitic acid (PA)-treated hepatocytes, whereas C7ORF41 knockdown showed the opposite effects. Mechanistically, we found the anti-inflammatory role of C7ORF41 was attributed to the suppression of NF-κB p65-mediated induction of inflammatory cytokines. Moreover, we demonstrated that the suppression of C7ORF41 expression in hepatocytes is due to JNK activation, which promotes c-Jun-mediated transcriptional repression of C7ORF41. In conclusion, our findings suggested that a c-Jun/C7ORF41/NF-κB regulatory network controls the inflammatory response and lipid accumulation in NAFLD and may benefit the development of novel and promising therapeutic targets for NAFLD.

[1]  E. Wagner,et al.  AP-1: a double-edged sword in tumorigenesis , 2003, Nature Reviews Cancer.

[2]  Alexis M. Kalergis,et al.  Innate Immunity and Inflammation in NAFLD/NASH , 2016, Digestive Diseases and Sciences.

[3]  B. Neuschwander‐Tetri,et al.  Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings , 2011, Hepatology.

[4]  Richard A. Flavell,et al.  Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity , 2012, Nature.

[5]  G. Targher,et al.  Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis , 2013, Nature Reviews Gastroenterology &Hepatology.

[6]  W. Li,et al.  Novel function of the chromosome 7 open reading frame 41 gene to promote leukemic megakaryocyte differentiation by modulating TPA-induced signaling , 2014, Blood Cancer Journal.

[7]  Gianluca Svegliati-Baroni,et al.  Lipotoxicity and the gut-liver axis in NASH pathogenesis. , 2018, Journal of hepatology.

[8]  Julia C. Engelmann,et al.  Increased expression of c-Jun in nonalcoholic fatty liver disease , 2013, Laboratory Investigation.

[9]  M. Abraham,et al.  Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis , 2012, Hepatology.

[10]  A. Sanyal,et al.  Lipotoxicity in NASH. , 2012, Journal of hepatology.

[11]  T. Kerppola,et al.  Close encounters of many kinds: Fos-Jun interactions that mediate transcription regulatory specificity , 2001, Oncogene.

[12]  E. Wagner,et al.  Promoter Specificity and Biological Activity of Tethered AP-1 Dimers , 2002, Molecular and Cellular Biology.

[13]  H. Tilg,et al.  Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis , 2010, Hepatology.

[14]  Keith G. Tolman,et al.  Spectrum of Liver Disease in Type 2 Diabetes and Management of Patients With Diabetes and Liver Disease , 2007 .

[15]  G. Marchesini,et al.  NASH: From liver diseases to metabolic disorders and back to clinical hepatology , 2002, Hepatology.

[16]  Y. Koyama,et al.  Liver inflammation and fibrosis. , 2017, The Journal of clinical investigation.

[17]  W. Wahli,et al.  Peroxisome proliferator–activated receptor α mediates the adaptive response to fasting , 1999 .

[18]  H. Tilg,et al.  Insulin resistance, inflammation, and non-alcoholic fatty liver disease , 2008, Trends in Endocrinology & Metabolism.

[19]  Q. Anstee,et al.  Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum. , 2016, Annual review of pathology.

[20]  A. Zou,et al.  Pathogenesis of Nonalcoholic Steatohepatitis: Interactions between Liver Parenchymal and Nonparenchymal Cells , 2016, BioMed research international.

[21]  Zhi‐Gang She,et al.  Hepatocyte DUSP14 maintains metabolic homeostasis and suppresses inflammation in the liver , 2018, Hepatology.

[22]  H. Blum,et al.  The transcription factor c‐Jun protects against sustained hepatic endoplasmic reticulum stress thereby promoting hepatocyte survival , 2012, Hepatology.

[23]  L. Henry,et al.  NAFLD AND NASH: Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention , 2018 .

[24]  Guido Gerken,et al.  The interaction of hepatic lipid and glucose metabolism in liver diseases. , 2012, Journal of hepatology.

[25]  Hongliang Li,et al.  Hepatic Interferon Regulatory Factor 6 Alleviates Liver Steatosis and Metabolic Disorder by Transcriptionally Suppressing Peroxisome Proliferator‐Activated Receptor γ in Mice , 2019, Hepatology.

[26]  E. Brunt,et al.  Nonalcoholic fatty liver disease: pathology and pathogenesis. , 2010, Annual review of pathology.

[27]  T. Lawrence The nuclear factor NF-kappaB pathway in inflammation. , 2009, Cold Spring Harbor perspectives in biology.

[28]  A. Schmitt-Graeff,et al.  The transcription factor c-Jun/AP-1 promotes liver fibrosis during non-alcoholic steatohepatitis by regulating Osteopontin expression , 2019, Cell Death & Differentiation.

[29]  Yong-Jian Wang,et al.  ZNF300 stimulates fatty acid oxidation and alleviates hepatosteatosis through regulating PPARα. , 2019, The Biochemical journal.

[30]  J. Olefsky,et al.  Insulin sensitivity: modulation by nutrients and inflammation. , 2008, The Journal of clinical investigation.

[31]  S. Shoelson,et al.  Inflammation and the IKKβ/IκB/NF-κB axis in obesity- and diet-induced insulin resistance , 2003, International Journal of Obesity.

[32]  G. Tarantino,et al.  JNKs, insulin resistance and inflammation: A possible link between NAFLD and coronary artery disease. , 2011, World journal of gastroenterology.

[33]  A. Gentilini,et al.  Molecular Pathogenesis of NASH , 2016, International journal of molecular sciences.

[34]  Hongliang Li,et al.  The E3 ligase tripartite motif 8 targets TAK1 to promote insulin resistance and steatohepatitis , 2016, Hepatology.

[35]  Z. Ronai JNKing Revealed. , 2004, Molecular cell.

[36]  F. Bessone,et al.  Molecular pathways of nonalcoholic fatty liver disease development and progression , 2018, Cellular and Molecular Life Sciences.

[37]  S. Kaneko,et al.  Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. , 2007, Gastroenterology.

[38]  F. Gonzalez,et al.  Hepatic PPARγ and LXRα independently regulate lipid accumulation in the livers of genetically obese mice , 2014, FEBS letters.

[39]  S. Akira,et al.  c‐Jun mediates hepatitis C virus hepatocarcinogenesis through signal transducer and activator of transcription 3 and nitric oxide–dependent impairment of oxidative DNA repair , 2010, Hepatology.

[40]  D. Kardassis,et al.  A Dominant Negative Form of the Transcription Factor c-Jun Affects Genes That Have Opposing Effects on Lipid Homeostasis in Mice* , 2007, Journal of Biological Chemistry.

[41]  Y. Lyou,et al.  Maturin is a novel protein required for differentiation during primary neurogenesis. , 2013, Developmental biology.

[42]  Zan Huang,et al.  ZNF300 tight self-regulation and functioning through DNA methylation and histone acetylation , 2017, Cell & Bioscience.

[43]  Hongliang Li,et al.  Hepatic Interferon Regulatory Factor 6 Alleviates Liver Steatosis and Metabolic Disorder by Transcriptionally Suppressing Peroxisome Proliferator‐Activated Receptor γ in Mice , 2019, Hepatology.

[44]  Yujie Ren,et al.  Induction of INKIT by Viral Infection Negatively Regulates Antiviral Responses through Inhibiting Phosphorylation of p65 and IRF3. , 2017, Cell host & microbe.

[45]  E. Latz,et al.  Activation and regulation of the inflammasomes , 2013, Nature Reviews Immunology.

[46]  C. Byrne,et al.  NAFLD: a multisystem disease. , 2015, Journal of hepatology.